On 16 March 2020 Trimph closed a $5m Series A funding round.  Ryder Innovation Fund is an early stage venture capital limited partnership specialising in medtech and tech opportunities. The Ryder Innovation Fund committed to fund the entire Series A raising of $5m, subject to agreed milestones.

Commenting on the Trimph investment, Ryder Innovation Fund principal and co-founder David Bottomley stated: 

“We are incredibly excited about this innovative platform technology. Ali and the team have developed a unique class of injectable scaffolds addressing a broad range of indications, including bone regeneration, dental reconstruction, aesthetics, cartilage and a bioactive pipeline addressing osteoarthritis. The technology is fully synthetic, inert and resorbable and importantly, from a clinical standpoint, the products’ physical properties are optimal i.e. injectable and temperature responsive. The early clinical data is very promising and we envisage a number of commercial licensing agreements to be struck for the various product applications while the team plans for future developments in its core business”.

Mr Bottomley will join the Board of Trimph.